▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3696 by analyst upside · 2026-11-13
ABBV
AbbVie Inc.
Healthcare · Market Cap $520B · P/E 50.6x
ANALYST PRICE TARGET
+5.9%
implied upside to consensus target
Current Price $294.45
Consensus Target $311.81
Bull Target $350.0
Bear Target $237.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
14
Hold
4
Sell
2
52-Week Low $190.75
52-Week High $302.93
YTD Return +32.3%
FUNDAMENTALS
Market Cap $520B
P/E Ratio (TTM) 50.6x
Forward P/E 18.2x
EPS (TTM) $5.82
PEG Ratio 0.59
Dividend Yield 2.35%
Revenue (TTM) $66.0B
Profit Margin 15.7%
52-WEEK RANGE
52-Week Low $190.75
52-Week High $302.93
Current Price $294.45
Bear Target $237.0
Bull Target $350.0
● Now $294.45 ● Target $311.81
TRADING DATA
Avg Volume 4.8M
YTD Return +32.3%
Analyst Count 26
Consensus Buy
Upside to Target +5.9%
Last Updated 2026-11-13

ANALYST SUMMARY

AbbVie Inc. (ABBV) is currently trading at $294.45 with a Wall Street consensus price target of $311.81, implying potential upside of 5.9% over the next 12 months. 26 analysts currently cover ABBV, with a consensus rating of Buy - 77% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $350.0, while the most cautious has a target of $237.0.

ABBV operates in the Healthcare sector with a market capitalisation of $520B. The stock is up 32.3% year-to-date and is currently trading near the upper end of its 52-week range of $190.75 – $302.93.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

UNH +17.5%
UnitedHealth Group Incorporated
$363B · P/E 23.1x · Buy
AZN +12.9%
AstraZeneca PLC
$286B · P/E 26.1x · Buy
LLY +2.3%
Eli Lilly and Company
$1.27T · P/E 46.3x · Buy
TMO +8.2%
Thermo Fisher Scientific Inc.
$259B · P/E 36.9x · Buy
ABT +10.9%
Abbott Laboratories
$186B · P/E 40.0x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ABBV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Neutral → Neutral 2026-11-02 33% win rate (6 calls)
Leerink Partners - Reiterated
Outperform → Outperform 2026-11-02 29% win rate (7 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-11-02 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-11-02 62% win rate (8 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-11-02 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-11-02 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-11-02 Building track record
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-11-02 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →